HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $13.60, but opened at $14.38. HUTCHMED shares last traded at $14.18, with a volume of 39,504 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HCM shares. Wall Street Zen downgraded shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.

HUTCHMED Trading Up 0.6%

The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. The business has a fifty day moving average price of $14.06 and a 200 day moving average price of $14.81.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Blue Trust Inc. boosted its stake in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after acquiring an additional 3,532 shares in the last quarter. XY Capital Ltd purchased a new position in HUTCHMED during the 4th quarter worth approximately $673,000. Summit Trail Advisors LLC increased its position in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after buying an additional 1,647 shares during the period. ABC Arbitrage SA purchased a new stake in HUTCHMED in the fourth quarter valued at approximately $500,000. Finally, OLD Mission Capital LLC acquired a new stake in shares of HUTCHMED in the fourth quarter valued at approximately $230,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.